Benufutamab
Modify Date: 2024-01-16 10:44:02
Benufutamab structure
|
Common Name | Benufutamab | ||
|---|---|---|---|---|
| CAS Number | 2109730-69-8 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BenufutamabBenufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects[1]. |
| Name | Benufutamab |
|---|
| Description | Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Benufutamab（GEN1029；HexaBody-DR5/DR5；20 µg/mL；24 小时）在多发性骨髓瘤 (MM) 细胞中诱导强效细胞毒性[1]。 Cell Viability Assay[1] Cell Line: Multiple myeloma (MM) cells Concentration: 20 µg/mL Incubation Time: 24 hours Result: Induced potent cytotoxicity. |
| In Vivo | Benufutamab（GEN1029；HexaBody-DR5/DR5；0.5-2 mg/kg；腹腔注射；每周一次；持续 9 周）在结直肠癌的 PDX 模型中显示出显着的抗肿瘤活性[2]。 Animal Model: Balb/c athymic nude or NU/NU nude mice injected with colorectal cancer (CRC) cells[2] Dosage: 0.5 mg/kg, or 2 mg/kg Administration: i.p.; once a week; for 9 weeks Result: Showed significant antitumor activity. |
| References |
| No Any Chemical & Physical Properties |